Full Press Release Details
Dr. Eric R. Mortensen, M.D., Ph.D., Clinical
Joins CytoSorbents as Chief Medical Officer
Strengthens clinical trial capability
with more than two decades of proven and successful clinical trial development expertise
MONMOUTH JUNCTION, NJ - May 30, 2017 - CytoSorbents
Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb
blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that
Dr. Eric R. Mortensen, M.D., Ph.D., will join CytoSorbents as Chief Medical Officer, starting full-time on June 1, 2017.
Dr. Phillip Chan, M.D., Ph.D., CytoSorbents'
Chief Executive Officer stated, "Dr. Mortensen has led clinical development of key programs for some of the largest pharmaceutical
companies in the world, including Pfizer's novel rheumatoid arthritis therapy, Xeljanz , which has achieved approximately
$1 billion in annual worldwide sales. He brings more than two decades of proven and successful clinical trial development expertise
to the company, as well as a wealth of knowledge and experience in immunology, inflammation, and clinical medicine. We are thrilled
to welcome Dr. Mortensen to the executive team at CytoSorbents."
Dr. Mortensen commented, "CytoSorbents
is at an exciting phase in the clinical and scientific validation of its unique immunotherapy approach, and I am eager to contribute
my significant clinical development experience to advance this important technology. CytoSorb has been used successfully in a wide
range of challenging inflammatory conditions, demonstrating the promise of blood purification as an alternative to drugs and biologics.
Our goal now is to design and execute the appropriate, well-designed studies to make CytoSorb standard of care for many of these
conditions. I look forward to building upon the recent REFRESH I cardiac surgery trial to advance CytoSorb through a registration
trial towards potential U.S. approval. In addition, I am fascinated by the easily modified core polymer, which has led to many
new experimental treatments for blood transfusion applications, hyperkalemia, drug overdose, and toxin-mediated disease. This flexibility,
as well as the ability to be adapted to many different modes of administration, creates a wealth of opportunities to develop new
therapies. I believe that CytoSorb and our related technologies represent a breakthrough paradigm in the approach to inflammation
As Vice President & Therapeutic Area
Clinical Head for Inflammation and Immunology at Pfizer from 2014 to 2016, Dr. Mortensen led the company's global, late-stage development
organization for programs in inflammatory diseases including studies for Enbrel and Xeljanz . As the Clinical Inflammation
Development Strategy Lead and co-chair for Inflammation's Therapeutic Area Strategy Team (TAST), he ensured an integrated
approach to the development of medicines across the different indications within Inflammation and Immunology. Dr. Mortensen previously
held positions of increasing responsibility as the Vice President, Global Medicine Development Group Global Lead for Xeljanz and
Assistant Vice President and Global Therapeutic Area Director for Enbrel. Previously at GlaxoSmithKline, he led clinical programs
for the reintroduction of alosetron to the US market, the registration program for alvimopan, and medical affairs programs for
assets within Women's Health, Urology, Acute Care, Gastrointestinal and Ophthalmologic business units. Prior to this,
at Merck Research Laboratories, he was responsible for registration studies of the COX2 inhibitors rofecoxib and etoricoxib.
Dr. Mortensen received an A.B. in Biochemistry
from Harvard College, an M.D. from the Harvard University and Massachusetts Institute of Technology Division of Health Sciences
and Technology (HST), and a Ph.D. in Biophysics at the Harvard Graduate School of Arts and Sciences where he studied the transduction
of membrane-bound hormone receptor's binding into intracellular activation of metabolic activity and cellular proliferation.
Dr. Mortensen completed an internship and residency in Internal Medicine at the Massachusetts General Hospital and a fellowship
in Gastroenterology at the University of Michigan Medical Center, Ann Arbor.
CytoSorbents also announced that Dr. Robert
H. Bartlett, M.D. will retire as Chief Medical Officer, but will continue working closely with the company as a consultant and
as Co-chair of the Cardiac Surgery Advisory Board with Dr. Joseph Zwischenberger, M.D. through the next anticipated REFRESH 2 cardiac
Dr. Chan stated, "For nearly nine
years, Dr. Bartlett has served as Chief Medical Officer of CytoSorbents and has helped guide the company through multiple key clinical
studies, including the successfully completed REFRESH I cardiac surgery trial, our European Union approval of CytoSorb, and commercialization
of CytoSorb worldwide. A trusted advisor, an experienced and practical clinician, and a legend in the field of extracorporeal membrane
oxygenation, we are pleased to continue working with Dr. Bartlett on a consulting basis. On behalf of the Board of Directors and
the entire company, we thank Dr. Bartlett for his many outstanding contributions towards the success of the company."
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is
a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is
approved in the European Union with distribution in 43 countries around the world, as a safe and effective extracorporeal cytokine
adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause
massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and
pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective
treatments exist. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines
and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed
its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated the
safety and efficacy of free hemoglobin reduction with intra-operative CytoSorb use in a heart-lung machine during complex
cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support U.S. FDA approval.
CytoSorb has been used safely in more than 23,000 human treatments to date.
CytoSorbents' purification technologies
are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess
of $18 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of
Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company
has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents
and multiple applications pending, including CytoSorb-XL, HemoDefend , VetResQ , ContrastSorb, DrugSorb, and others.
For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or
Forward-Looking Statements
This press release includes forward-looking
statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations
and contentions and are not historical facts and typically are identified by use of terms such as "may," "should,"
"could," "expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some forward-looking statements are expressed differently.
You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations,
but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which
could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form
10-K, filed with the SEC on March 3, 2017, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required under the Federal securities laws.
Cytosorbents Contact:
Public Relations Contact:
Pascale Communications